Synopsis: In this episode of Biotech2050, Scott Megaffin, CEO of Adiso Therapeutics, shares valuable insights on the challenges and opportunities in the biotech industry. His deep involvement in the pharmaceutical and biopharmaceutical sector has shaped his strategic approach to leadership and business management. Scott emphasizes the importance of a CEO's versatility and willingness to undertake any task, no matter how small, and also highlights the burden of proving the value of differentiation in a small company. The conversation delves into the significance of collaboration with research institutions and strategic partners, underlining the importance of differentiation and collaboration in competitive markets. Scott’s reflections on his career journey and the development of Adiso's asset Adso 51 provide valuable lessons for professionals and entrepreneurs in the field, making this episode a must-listen for biotech entrepreneurs and professionals seeking to enhance their ability to differentiate and collaborate in competitive markets. Biography: Scott joined Adiso Therapeutics as Chief Executive Officer in January 2022, bringing more than 35 years of successful industry leadership, having held multiple senior executive, CEO and board director roles during his career at both Fortune 500 pharmaceutical and emerging biotechnology companies. Among Mr. Megaffin’s many career leadership roles, he previously served as the CEO of Adastra Pharmaceuticals Inc., a pioneer in the pursuit of better treatment options for high unmet need cancers, where he led the company from early informative to clinical-stage advancement of first-in-class clinical programs, and ultimately to its acquisition by Cothera Bioscience. Earlier, he served as a President of Churchill Pharmaceuticals, Inc., leading the organizational growth and development of a fully differentiated oral oncology asset for metastatic castrate resistant prostate cancer through FDA approval and ultimately a transaction to Sun Pharma. Mr. Megaffin has held numerous global strategic and operational positions of increasing responsibility within Onconova, Schering-Plough, Yamanouchi, Pharmacia, and Bristol-Myers Squibb. During his career Scott has led six global drug development programs resulting in regulatory approvals. He possesses far reaching knowledge in a broad number of therapeutic categories including oncology, anti-infectives, inflammation, pain, critical care, and virology. Mr. Megaffin currently serves as a board member of Adastra and on the Board of Directors for BioNJ, the biotechnology and life science organization of New Jersey. Mr. Megaffin holds a B.S. in Biology from Pittsburg State University.

Synopsis: In this episode of the Biotech2050 podcast, Dr. Mathai Mammen, CEO of FogPharma, shares valuable insights into the future trends of the biotech industry and the development of peptide-based therapeutics. Dr. Mammen's extensive career trajectory, from academia to leading pharmaceutical organizations, provides a comprehensive understanding of the industry's evolution and the pivotal roles he played at Theravance, Merck, and J&J. The episode delves into the significance of intracellular protein interactions and FogPharma's focus on developing helicon peptides to address this unmet need. Dr. Mammen's emphasis on a moonshot culture at FogPharma, coupled with his strategic approach to commercial success in biotech, makes this episode essential listening for executives in the biotech industry who are looking to stay ahead of future trends and gain insights into the innovative approaches shaping the industry's landscape. His profound knowledge and experience position him as a thought leader, offering invaluable perspectives on the challenges and opportunities in biotech, making this episode a compelling resource for industry executives seeking to implement strategies for commercial success in the biotech sector. Biography: Mathai Mammen is a world-renowned innovator in drug discovery, development, and team and company building. He brings significant global R&D and corporate leadership experience to his role as CEO, President and Chairman at FogPharma. Most recently, Mathai was a member of the executive committee at Johnson & Johnson, where he served as executive vice president of pharmaceuticals, R&D. During his tenure, he spearheaded a significant evolution of Janssen’s R&D, one of the largest R&D organizations in the world. Mathai was a key leader in Johnson & Johnson’s bold foray into COVID vaccines and he helped drive Janssen’s substantial growth to become one of the top pharmaceutical companies globally. Under Mathai’s leadership, Janssen R&D executed 40+ acquisitions and licenses and 350+ strategic partnerships and collaborations. A central pillar of his strategy was data science, which he used to couple recent revolutionary advances in data, compute and algorithmic approaches to every aspect of discovering and developing medicines. Mathai led his team to global approvals of eight new medicines, including Tremfya™, Darzalex Faspro™, Balversa™, Carvykti™, Rybrevant™, Ponvory™, Spravato™ and Tecvayli™, with many additional global approvals for expanded indications of marketed products. Prior to his role at Johnson & Johnson, Mathai served as senior vice president at Merck, where he was responsible for multiple research areas, including cardiovascular, metabolic and renal diseases, immunology, oncology and immuno-oncology. Before Merck, he led R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides. Under his leadership, Theravance advanced a robust pipeline of multiple development-stage compounds resulting in five approved pharmaceutical products, and separated into two companies: Theravance Biopharma, Inc. and Innoviva, Inc. In addition to his extensive corporate experience, Mathai currently serves on the board of directors of 10x Genomics, Inc. He has authored more than 150 peer-reviewed publications and patents. Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

Synopsis: In the recent episode of Biotech2050, Ken Galbraith, CEO of Zymeworks, shares profound insights into the biotech industry, leadership, and the complexities of developing innovative treatments for challenging cancers. Galbraith's accidental entry into biotech in 1987, despite lacking prior experience, led to his pivotal role in establishing a successful biotech company in Canada, shaping the industry significantly. Throughout the conversation, he emphasizes the critical elements of leadership, continuous learning, and the relentless pursuit of groundbreaking science. Galbraith's focus on addressing unmet medical needs and navigating the dynamic biotech landscape offers valuable lessons for current and aspiring biotech leaders. Furthermore, his involvement in developing innovative biologic structures for difficult-to-treat cancers, exemplified by Zymeworks' mission, underscores the episode's relevance for biotech professionals seeking insights into leadership, growth, and pioneering solutions for challenging medical conditions. Galbraith's wealth of experience and strategic approach provide a compelling narrative that makes this episode an invaluable resource for understanding the keys to success in the dynamic and impactful field of biotechnology. Biography: Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Liminal BioSciences Inc., Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Synopsis: In this episode of Biotech2050, host Alok Tayi engages in a profound conversation with Craig Chambliss, CEO and co-founder of Neurellis, delving into their strategic advancements in precision therapies for CNS diseases. Chambliss shares his journey, highlighting his finance and accounting background and pivotal roles in pharmaceutical companies like Bristol Myers Squibb and Alza Pharmaceuticals. His passion for impactful drug delivery technologies led to the launch of life-changing products, including an intranasal diazepam program for seizure emergencies, ultimately culminating in the founding of Neurellis in 2008. With the approval of their product Altoco in 2020, Neurellis addressed unmet needs in the epilepsy market, emphasizing the significance of a passionate team and a foundational product for successful clinical trials and market access. The conversation emphasizes the importance of precision therapies in the CNS space, collaboration for innovative solutions, and the potential of Neurellis' pipeline in addressing severe epileptic encephalopathies. Chambliss's insights into the strategic management of a biotech company, the utilization of platform technologies, and the evolving landscape of the biotech industry offer compelling takeaways for biotech executives seeking strategic insights. This episode provides a valuable opportunity to gain strategic insights into precision therapies for CNS diseases and the journey of a successful biotech company. Biography: Craig Chambliss’ 30-year tenure in the biopharma and drug delivery sectors has largely specialized in rare diseases of the central nervous system (CNS) and epilepsy. As the co-founder, CEO, and President of Neurelis, he has orchestrated the company's growth, securing over $300M in funding and guiding its evolution into a fully integrated organization, spanning from early-stage development to commercialization. Before his current role at Neurelis, Mr. Chambliss played a key part in reshaping NextWave Pharmaceuticals into a CNS-focused entity, serving as its Chief Business Officer. Under his leadership, NextWave secured $45M in Series C financing and was later acquired by Pfizer in a deal value exceeding $700M in 2012. Prior to NextWave, he also helped rebuild Questcor Pharmaceuticals as a CNS-focused organization, where he led commercial operations supporting the relaunch of Acthar® Gel for the treatment of a rare epilepsy disorder in pediatric patients. Mr. Chambliss's pharmaceutical journey began in sales at Bristol Myers Squibb and continued through various roles at Alza Pharmaceuticals and Elan Pharmaceuticals. In 2001, he helped launch Xcel Pharmaceuticals, a CNS startup focusing on epilepsy treatment, leading to a successful acquisition by Valeant Pharmaceuticals in 2005 for $280M. His academic foundation includes Bachelor of Science degrees in Finance and Accounting from Missouri State University.

Synopsis: On the Biotech2050 podcast, Tuyen Ong, CEO at Ring Therapeutics and CEO partner at flagship pioneering, shared his journey from a medical background to leading innovative gene therapy companies, highlighting the importance of cross-disciplinary expertise in driving biotech advancements. His insights into the gene therapy landscape and the future of genetic medicine, including its intersection with artificial intelligence, offer valuable perspectives for biotech professionals seeking to navigate the complexities of precision medicine and drug development. Tuyen's emphasis on fostering a values-driven culture, leveraging innovation in genetic medicine, and maintaining a resilient mindset in the face of industry challenges serves as a guiding light for aspiring biotech professionals and organizations striving to make a positive impact on global health. With a deep understanding of the industry's challenges and opportunities, Tuyen's discussion with host Rahul Chaturvedi provides a comprehensive exploration of culture-building, precision medicine, and strategic growth within the biotech industry, making it a must-listen for professionals seeking insights into innovative advancements in precision medicine. Biography: Tuyen is a physician, bioentrepreneur and Ring’s CEO. Prior to joining Ring Therapeutics in September 2020, Tuyen served as Senior Vice President at Biogen and as Chief Development Officer at Nightstar Therapeutics until its acquisition by Biogen. During this time, he was involved with the company’s public listing on the NASDAQ, corporate and gene therapy strategy, investor, and M&A activities. Tuyen brings over 20 years of clinical and drug development experience from both large pharma and biotech, working in the fields of genetics, ophthalmology, and rare disease at PTC Therapeutics Inc., Bausch and Lomb Inc. (acquired by Valeant Pharmaceuticals International, Inc.), and Pfizer. Tuyen holds an MD from the University College London and an MBA from New York University Stern School of Business. He is a member of the Royal College of Ophthalmologists and a Churchill Fellow.

Synopsis: In a recent episode of Biotech2050, hosted by Alok Tayi, Kristen Fortney, CEO of BioAge, provides valuable insights into the evolving landscape of aging biology and the innovative approach BioAge is taking to identify therapeutic targets. Kristen's background in aging biology, genetics, and statistics underscores her expertise in the field. The conversation delves into the shift towards translational research in aging biology, emphasizing the increasing interest in targeting aging-related diseases such as heart disease, Alzheimer's, and cancer. Kristen highlights the importance of leveraging human data, utilizing relevant animal models, and strategically allocating resources to enhance the success rate of drug development in the biotech industry. She shares BioAge's unique approach to drug discovery, focusing on human data sets collected over decades, and emphasizes the importance of identifying novel targets for aging-related diseases. This episode is essential listening for entrepreneurs in biotech and aging research, providing valuable insights into the current state and future prospects of the field, and highlighting the potential for driving innovation through collaboration and strategic partnerships. Biography: Kristen leads BioAge in its mission to develop a broad pipeline of therapies that target metabolic aging by harnessing the science of human longevity.Kristen draws from a deep background in geroscience and systems biology to advance BioAge’s data-driven approach to identifying and targeting the molecular pathways that drive aging. Kristen received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research. She has over 15 years of experience developing novel bioinformatics approaches for data-driven investigation into the mechanisms of aging and age-related disease, with 18 published papers spanning computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity. BioAge recently closed a Series D financing bringing the company’s total raise above $300 million.

Synopsis: In this episode of the Biotech2050 podcast, Chris Gibson, the co-founder and CEO of Recursion, shares insights on the intersection of technology and biotech, emphasizing the importance of adaptability and diverse partnerships in driving innovation. Gibson's journey from pursuing an MD-PhD program with a focus on merging engineering and medicine to founding Recursion showcases his deep understanding of the evolving biotech landscape. His experience navigating the capital markets and proactive decision-making in response to market conditions offers valuable lessons for entrepreneurs in the industry. The episode delves into the challenges and opportunities in the biotech sector, highlighting the transformative potential of technology and the significance of embracing entrepreneurship and risk-taking. Gibson's emphasis on building diverse teams and the impact of partnerships serves as a compelling reason for entrepreneurs and leaders in the biotech industry to listen to this episode, providing valuable insights and strategies for navigating the rapidly changing biotech landscape. Biography: Chris Gibson developed the technology and approach that seeded Recursion as part of his MD/PhD work in the lab of Co-Founder Dr. Dean Li (current President of Merck Research Labs) while at the University of Utah. After completing his Ph.D., Chris left medical school to build Recursion into the rapidly growing company it is today. Chris is a graduate of Rice University with degrees in bioengineering and management. Chris serves on the Board of BioHive, the public-private partnership driving expansion of Utah's life-science ecosystem, the fastest growing in the nation. Chris is also active as an advisor and mentor, both formally and informally, of many young biotech founders. Chris enjoys cycling on both the road and the trails that cut through Utah's great wilderness, as well as spending time with family.

Synopsis: Christian Angermayer, a prominent investor and entrepreneur in the biotech industry, shares valuable insights in the Biotech2050 podcast, shedding light on the challenges and opportunities within the sector. Drawing from his extensive experience, Angermayer emphasizes the importance of making biotech more accessible to a broader audience while maintaining the integrity of the science. He discusses the need for a broader investor community in biotech to unlock more capital and stimulate early-stage science funding. His unique perspective highlights the intersection of tech and biotech, emphasizing the potential for collaboration and innovation. By implementing Angermayer's insights, entrepreneurs can gain a comprehensive understanding of the evolving landscape of biotech and harness new opportunities for growth and development. By incorporating Angermayer's insights, entrepreneurs can gain essential knowledge of the evolving biotech landscape and capitalize on new opportunities for growth and development. Biography: Christian Angermayer is a serial entrepreneur and investor who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives. Christian’s family office and private investment firm, Apeiron Investment Group, has more than USD 2.5 billion under management and 50 people in London, New York City, Abu Dhabi and Berlin. Apeiron focuses on Life Sciences, FinTech & Crypto, Future Tech and Experiences, Hospitality & Happiness. Over the past 20 years, Christian has founded three unicorns himself and has been the lead investor in four unicorns and two decacorns.

Synopsis: In this episode of the Biotech2050 podcast, David Kirn, CEO of 4D Molecular Therapeutics, shares invaluable insights for aspiring entrepreneurs in the biotech industry. Kirn discusses the development of his company's platform that integrates gene therapy and directed evolution to create innovative treatments for genetic diseases. By utilizing directed evolution, 4D Molecular Therapeutics has been able to invent an AAV vector that achieves safe and effective gene expression in the retina, targeting rare genetic diseases initially and subsequently expanding to larger markets. Kirn emphasizes the importance of balancing a strong platform with diverse product opportunities to decrease risk and increase the probability of success in the biotech landscape. Kirn's expertise and experience provide a compelling narrative that sheds light on the vital aspects of biotech entrepreneurship. Kirn emphasizes the importance of balancing a strong platform with diverse product opportunities to decrease risk and increase the probability of success in the biotech landscape. The episode delves into the tension between platform and product focus, offering guidance on fundraising and the regional dynamics of biotech investment. Kirn's expertise and experience provide a compelling narrative that sheds light on the vital aspects of biotech entrepreneurship, making this episode a must-listen for academic entrepreneurs looking to navigate the complexities of biotech investment and build traction in the industry. Biography: David Kirn, MD, is our co-founder and has served as our Chief Executive Officer since our inception in 2013. Dr. Kirn is also Adjunct Professor of Bioengineering and Molecular & Cellular Biology at UC Berkeley. Over his 30 year career, Dr. Kirn has co-founded and been CEO of four viral vector-based genetic medicines companies, three of which to date were either acquired or went public. Dr. Kirn also held senior clinical research and development positions at Onyx Pharmaceuticals (VP) and Celgene (SVP), and was a senior advisor to Novartis, Bayer, Pfizer, Biogen and others in the genetic medicines field. Dr. Kirn received a BA in Physiology (Departmental Citation; Phi Beta Kappa) from UC Berkeley in 1985, an MD (Alpha Omega Alpha) from UC San Francisco Medical School in 1989 and completed internal medicine residency training at Harvard Medical School, Brigham and Women’s Hospital (including a term as Chief Medical Resident at affiliated VA hospital). He has also completed hematology-oncology and clinical research fellowships at UC San Francisco and completed a certificate of business excellence from the Haas Business School at UC Berkeley. In 2013, he was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center.

Synopsis: In this episode of the Biotech2050 podcast, David Esposito, CEO of ONL Therapeutics, provides valuable insights into the challenges and opportunities in the field of ophthalmology. Esposito's extensive career journey, from the United States Military Academy to leading ONL Therapeutics, underscores his deep understanding of the industry. He offers a comprehensive analysis of the impact of the Inflation Reduction Act (IRA) on indication selection and the evolving capital market for biotech companies. The episode delves into the complexities of proving safety and tolerability in new mechanisms of action, the strategic shift in pursuing chronic indications, and the interplay between big pharma and early-stage biotechs in the current capital environment. Esposito's expertise and in-depth knowledge make this episode essential listening for ophthalmology professionals seeking to navigate industry challenges, understand the IRA's implications, and explore strategic partnerships for clinical development support.,In this episode of the Biotech2050 podcast, CEO of ONL Therapeutics, David Esposito, shares his extensive insights into the challenges and opportunities within the ophthalmology field. With a career spanning from the United States Military Academy to leading ONL Therapeutics, Esposito brings a wealth of experience and understanding to the topic. The discussion delves into the intricate impact of the Inflation Reduction Act (IRA) on indication selection and the dynamic capital market for biotech companies. Esposito's analysis covers the complexities of proving safety and tolerability in new mechanisms of action, strategic shifts in pursuing chronic indications, and the interplay between big pharma and early-stage biotechs in the current capital environment. Professionals in the ophthalmology sector will find this episode invaluable for gaining insights into industry challenges, comprehending the implications of the IRA, and exploring strategic partnerships for clinical development support. Biography: David is the former CEO of Armune BioScience where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The Company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017. David Esposito is an experienced healthcare executive who has built and scaled multiple companies that resulted in successful exits to strategic buyers. He was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing and commercial strategy for the US Division. David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.

Synopsis: In this episode of the Biotech2050 podcast, Jak Knowles, co-founder of Affini-T Therapeutics, shares valuable insights into the challenges faced by bootstrapped biotech companies and the significance of venture capital in the industry. Knowles discusses the importance of finding key partners and securing intellectual property early on, shedding light on the capital-intensive nature of drug development. Furthermore, he highlights the value of experienced investors and the impact of their investment source, emphasizing the advantage of being one of the first investments out of a fund. Knowles also provides an update on Affini-T Therapeutics' focus on developing therapies for solid tumors, offering a glimpse into their innovative approach using cell therapy and synthetic biology to address the challenges of the tumor microenvironment. His journey and expertise in navigating the intricacies of fundraising and company-building make this episode essential listening for entrepreneurs in the biotech industry, providing practical lessons and strategic insights for overcoming funding obstacles and driving success in the competitive landscape of biotechnology.,In this episode of the Biotech2050 podcast, Jak Knowles, the co-founder of Affini-T Therapeutics, offers valuable perspectives on the challenges encountered by bootstrapped biotech companies and the pivotal role of venture capital in the industry. Knowles emphasizes the significance of early intellectual property acquisition and strategic partnerships as critical factors in the capital-intensive arena of drug development. Furthermore, he underscores the importance of securing investment from experienced sources and elaborates on the benefits of being an early investment in a fund. Knowles also provides an update on Affini-T Therapeutics' focus on developing innovative therapies for solid tumors, showcasing the company's pioneering approach involving cell therapy and synthetic biology to address the complexities of the tumor microenvironment. With his wealth of experience and expertise, Knowles offers essential insights for biotech entrepreneurs, providing actionable strategies and valuable lessons for navigating the funding landscape and achieving success in the competitive biotechnology sector. Biography: Jak Knowles, MD, is Co-Founder, President and Chief Executive Officer of Affini-T Therapeutics. He has more than two decades of R&D, management, and entrepreneurial experience in the life science industry. Prior to launching Affini-T, Jak served as Co-founder and Chief Business Officer for Metagenomi, a next-generation gene editing company based in Berkeley, California. Jak was previously Head of Pharma Venture Investments for Leaps by Bayer, where he helped lead Metagenomi’s initial seed financing and early strategy serving on Metagenomi’s Board of Directors. Before joining Bayer, Jak served as Chief Executive Officer of CytoSen Therapeutics, where he developed Natural Killer immune cell therapies for oncology indications. In 2016, Jak co-founded and launched Exonics Therapeutics, a CRISPR gene-editing company, serving as President and interim-Chief Executive Officer. Jak previously served on the Board of Directors for Century Therapeutics, Exonics Therapeutics, Metagenomi Technologies, Triumvira Immunologics, and Pyxis Oncology. Jak earned his MD from Stanford University where he graduated with honors in biomedical research, and an undergraduate degree in biology from Binghamton University

Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women’s cancers. We’re excited to welcome Sean back to the podcast – he last appeared on episode 130 in late 2022. Sean provides an update on all the exciting things that have happened at Olema since then, including an update on their lead product candidate. Sean reflects on navigating the challenging biotech market environment over the past year, making careful spending decisions, and raising significant capital to extend Olema’s runway. He also offers advice to first-time CEOs on building a strong support network to guide company growth. Biography: Dr. Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. He is also a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.

Synopsis: Troy Wilson, Ph.D., J.D., is the President and CEO of Kura Oncology, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Troy talks about his experiences being a CEO and the differences in responsibility between being a CEO and a board member. He also shares what it takes to have a productive board for a biotech company. He discusses recruiting at both the team level and the board level and the qualities that he looks for in a candidate. He shares where he thinks cancer drug development is headed, where it needs to head and where he thinks there’s unmet need. Finally, he talks about the work they’re pursuing at Kura and where they are from a development perspective. Biography: Troy E. Wilson, Ph.D., J.D., is one of Kura’s Co-founders and has served as our President and Chief Executive Officer and as the Chairman of our Board of Directors since our inception in August 2014. Previously, Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., a privately held biopharmaceutical company, and its parent company Araxes Pharma LLC from July 2012 to March 2019 and as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly held biopharmaceutical company, from November 2012 to February 2019. Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privately held biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceutical Company Limited. He has also been a member of the Board of Directors of Puma Biotechnology, Inc., a publicly held biopharmaceutical company, since October 2013, Chairman and a member of the Board of Directors of Avidity Biosciences, Inc., a publicly held biopharmaceutical company, since February 2019 and November 2012, respectively, Executive Chairman and a member of the Board of Directors of Wellspring Biosciences since February 2019 and July 2012, respectively, and a member of the Board of Managers of Araxes Pharma LLC since July 2012. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.

Synopsis: Keith Gottesdiener, MD, and Jeremy Duffield, MD, PhD, FRCP, are the President & CEO and CSO, respectively, of Prime Medicine. Prime Medicine was founded to bring the promise of gene editing to patients. They use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Keith and Jeremy discuss the arc of their careers and how they go to where they are today. They talk about the differences working in big pharma vs. a smaller biotech like Prime. They discuss the importance of companies investing in safety and what they’ve learned in terms of indication selection frameworks within the context of gene editing. Finally, they talk about their goal of engaging in partnerships down the road, and the importance of having transparency within their organization. Biography: Keith Gottesdiener, MD is President and Chief Executive Officer of Prime Medicine and has served as a member of our Board of Directors since July 2020. From October 2011 until March 2020, Dr. Gottesdiener served as the Chief Executive Officer and a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company that develops therapeutics in rare genetic obesity. During that time, Rhythm submitted a New Drug Application for setmelanotide in two indications, for which setmelanotide was subsequently approved. Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania. He completed his residency and fellowship at the Brigham and Women’s Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children’s Hospital programs. After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory of Dr. Jack Strominger at the Dana Farber Cancer Institute. He then joined the faculty as an assistant professor at Columbia University, where he started an independent research laboratory with NIH RO-1 funding, ending his academic career as Associate Clinical Professor of Medicine at the time he left to join Merck in 1995. Jeremy Duffield, MD, PhD, FRCP, is the Chief Scientific Officer of Prime Medicine. He has many years of drug discovery experience at Vertex Pharmaceuticals and Biogen Inc. preceded by a distinguished career in academic medicine. Dr. Duffield has held several leadership roles, with focus in the fields of human genetics, innate immunity and regenerative medicine. He served as Global Head of Human Biology at Vertex Pharmaceuticals and as Vice President of Business Development where he and his team played important roles in discovering and advancing candidates to clinical studies in rare diseases including cystic fibrosis, a1-antitrypsin deficiency, sickle cell disease, FSGS and muscular dystrophies. Several candidates are now approved therapies. He was instrumental in building Vertex Cell and Genetic Therapies. At Biogen, Dr. Duffield served as Senior Research Fellow and Vice President with responsibilities in early research programs, as joint Head of Innate Immunity and Regenerative Medicine therapeutic area, and as Head of the Biogen Post-Doctoral program. There he contributed to advancing integrin inhibitors, TNF superfamily inhibitors and IRAK inhibitors to clinical evaluation for pulmonary fibrosis and autoimmune diseases. Dr. Duffield received his B.A. and M.D. (B.M., B.Ch.) from Oxford University and a Ph.D. in Immunology from the University of Edinburgh in the laboratory of Sir John Savill.

Synopsis: Brett Hall, Ph.D., is the CSO of Immuneering, a public, clinical-stage oncology company dedicated to developing medicines for broad populations of cancer patients by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Brett talks about his background in the military targeting nuclear missiles prior to becoming a scientist and some of the commonalities between working in the military and pharma/biotech. He shares his thoughts on AI and machine learning in drug development. He talks about Immuneering’s disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its pipeline. Finally, he discusses their focus on oncology and providing potential treatments for patients with advanced solid tumors. Biography: Brett Hall, Ph.D. has served as Chief Scientific Officer of Immuneering since November 2019. He also served as the Founder and Chairman of the board of directors of BioArkive, Inc., or BioArkive, a privately held biotechnology services company from January 2019 until December 2021. Prior to joining Immuneering, Dr. Hall served as the Chief Executive Officer of Asellus Therapeutics, LLC from July 2015 until May 2018. Dr. Hall served in roles of increasing responsibility with Johnson & Johnson from November 2008 until July 2014, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant® and Imbruvica® through clinical development. Subsequently, he served as the Head of Translational Medicine of Oncology at Medimmune, LLC, the biologics division of AstraZeneca Pharmaceuticals LP, from July 2014 until July 2015, before transitioning to executive discovery roles in biotechnology. He has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences, and holds multiple patents for drug pharmacology and discovery. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. Prior to Dr. Hall’s career in life sciences, he served in the United States Air Force and worked as an investment banker. Dr. Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University, and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children’s Research Hospital.

Synopsis: Ivana Magovčević-Liebisch, PhD, JD, is the President and CEO of Vigil Neuroscience, a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Ivana shares how sitting on boards of other companies has informed how she operates as CEO at Vigil. She talks about how she’s seen her role evolve as the company has grown over the last three years. She discusses the importance of having diversity and diversity of thought on the leadership team. She provides her perspective on neurology as a therapeutic area, where unmet needs still exist, and the challenges and opportunities in precision-based neurology. Finally, she shares her approach to building culture at Vigil. Biography: Ivana is an accomplished pharmaceutical and biotechnology executive focused on corporate excellence and execution. She has over 20 years of senior management experience in financing, strategic partnerships, M&A, clinical development, regulatory affairs, commercialization, legal and IP strategies, and preparation and execution of operating plans. Prior to Vigil, Ivana was Executive Vice President (EVP) and Chief Business Officer at Ipsen where she was responsible for fueling the pipeline through external innovation and led the External Innovation, Business Development and Alliance Management functions. Prior to Ipsen, Ivana was EVP, Chief Strategy and Corporate Development Officer at Axcella Health, Senior VP (SVP) and Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. She previously worked at Dyax Corp in management roles including EVP and Chief Operating Officer where she launched the company’s first drug, Kalbitor® for an orphan indication, Hereditary Angioedema, and at Transkaryotic Therapies, Inc. Ivana serves as a member of the Board of Directors for Aeglea BioTherapeutics, Inc. Ivana holds a PhD in Genetics from Harvard University and received her JD in High Technology law from Suffolk University Law School.

Synopsis: Bobak Azamian, MD, Ph.D., is the CEO and Chairman of Tarsus Pharmaceuticals, a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Bobby talks about his early years working in the venture capital space before founding his first company. He shares what it’s like running a publicly traded biotech for the first time and the evolution of his role over the years at Tarsus. He shares his viewpoint on unmet needs and the importance of having a true focus on what’s really happening to the patient. He talks about future indications they’re pursuing at the company and how he leverages learnings from the first programs they ran to what’s coming up next. Finally, he discusses the company’s decision to commercialize in-house versus with a partner and the challenges of taking the company public during the pandemic in 2020. Biography: Bobby cofounded Tarsus Pharmaceuticals, Inc. with Michael Ackermann in November 2016 and has served as its President and CEO since September 2018. He has served as the company’s Chairman since December 2022. Since its founding, Tarsus has established a leading team and culture and has completed successful fundraising efforts through multiple private and public financings and global partnerships. Tarsus recently secured FDA approval for its first product, XDEMVY™ (lotilaner ophthalmic solution) 0.25%, which is the first and only FDA-approved treatment in the United States for the eyelid disease Demodex blepharitis. Beyond XDEMVY, Tarsus continues to advance its pipeline into Phase 2 clinical studies evaluating therapies that have the potential to create new categories to treat other major diseases, including meibomian gland disease, rosacea, and Lyme disease prevention. Bobby has cofounded and led other novel therapeutics companies, including Vibrato Medical and Metavention, and currently serves on the board of Vibrato Medical and as Chairman of the board of Osanni Bio. Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer for a variety of life sciences companies. He also served on the board of the nonprofit organization Octane. Bobby trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Health Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications. Bobby enjoys sports, travel, arts and culture, and spending time in Newport Beach with his newborn son, wife, and dog.

Synopsis: Nima Farzan is the CEO of Kinnate Biopharma, a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs. Having started his biotech career in the late 90s, Nima discusses how his vision of leadership has evolved over the years. He talks about joining Kinnate in March of 2020 and the challenges of running the company and growing the team during a pandemic. He dives into the evolution of genomics over the last several years and what has surprised and impressed him about the genomic ecosystem as a whole. He discusses where Kinnate is from a development perspective and how he thinks about indication selection. Finally, he talks about how being an immigrant has shaped his approach to team building, culture and leadership style. Biography: Nima brings over two decades of executive leadership experience in the biopharma industry to our team. Prior to joining us, Nima spent seven years at PaxVax, where he was most recently President and CEO. While there, he successfully led a team of 250 people through a number of commercial product launches and negotiated the sale of PaxVax to Emergent BioSolutions in 2018. Prior to PaxVax, he was at Novartis AG in a series of roles of increasing responsibility, most recently as Vice President of US Marketing at Novartis’ Vaccines and Diagnostics division. Prior to Novartis, Nima worked at DoubleTwist, a pioneering genomics company, and was a consultant with Boston Consulting Group. He was a member of the founding Board of the Coalition for Epidemic Preparedness Innovations (CEPI). He is on the Executive Committee of the Northern California Chapter of Young President’s Organization (YPO) and a Trustee at the Hamlin School. He is also a Director of Keros Therapeutics (NASDAQ: KROS). He holds a BA in Human Biology from Stanford University and an MBA from the Harvard Business School.

Synopsis: Mark Litton, Ph.D., is the President and CEO of Athira Pharma, a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration for those suffering from Alzheimer’s, Parkinson’s disease, dementia, and more. Mark talks about being a CEO for the first time and what he’s learned. He discusses how the biotech ecosystem and its ability to raise capital for companies has changed over the last couple of years and how that’s informing how he’s operating at Athira. He talks about fundraising strategy and how he communicates with team members who perhaps haven’t been involved in fundraising cycles and value creation at biotech before. Finally, he shares how he thinks about business development and his approach to partnerships. Biography: Mark is President and CEO of Athira Pharma, a position he has held since October 2021. Previously, he served as Athira’s COO since July 2019. Prior to joining Athira, Mark served as the President and COO of Alpine Immune Sciences, Inc. Prior to that he spent more than 14 years at Alder Biopharmaceutical Inc., a publicly traded biopharmaceutical company, which was acquired by Lundbeck A/S. As co-founder and CBO, Mark helped build the business and oversaw finance, investor relations, deal making, business development, alliance management, human resources, and overall corporate strategy. While at Alder, Mark was directly responsible for raising over ~$1B in equity capital and led negotiations for numerous corporate alliances between biotech and pharmaceutical companies. Mark has a PhD in immunology from Stockholm University, an MBA from Santa Clara University and a BA in Biochemistry and Molecular Biology from UC Santa Cruz.

Synopsis: Ram Aiyar, Ph.D., MBA, is the President & CEO of Korro Bio. Korro Bio harnesses the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Having founded several companies, Ram talks about some of the non-obvious differences in terms of being senior leadership and founder of a company versus being CEO. He discusses his approach to fundraising and how it’s changed over time. He talks about the field of RNA editing, the evolution of that space, and where he sees it heading long term. Finally, he discusses where the company is from a pipeline building perspective and how he thinks about indication selection. Biography: Ram Aiyar, Ph.D., MBA, is the chief executive officer and president of Korro Bio and sits on the board of directors. Ram brings nearly two decades of diverse experience in biotech and pharma, working across all stages of development from launch to clinical to commercialization. He has a long history of launching and building biotech startups, and previously held a wide range of roles in finance, strategy, product development and venture capital. Most recently, he was a co-founder, chief financial officer and chief business officer at Corvidia Therapeutics, and eventually led its acquisition by Novo Nordisk for $2.1B. Prior to Corvidia, he was an entrepreneur-in-residence at BioHealth Innovation (BHI). Ram started his scientific career in research at Janssen Pharmaceuticals’ immunology group. He has also held leadership roles in corporate development, finance and strategy at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase. Ram received his M.S. and Ph.D. in electrical and computer engineering from Drexel University and an MBA in finance and business strategy from INSEAD (France/Singapore).